Our research and development team leverages its expertise across a variety of scientific disciplines to focus on identifying drug compounds for reformulation to achieve:
Our development pipeline is highlighted by two product candidates in Phase III clinical trials, arbaclofen ER, and RVL-1201, as well as multiple ANDAs pending regulatory approval and other products in various stages of development. Several of our pipeline products incorporate our proprietary Osmodex® drug delivery system.
Arbaclofen ER is an extended release formulation of arbaclofen, the R isomer of baclofen, that leverages our proprietary Osmodex® drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis.
In 2017, we initiated our second Phase III clinical trial to evaluate the efficacy of arbaclofen ER. We anticipate completing enrollment of the 510 patient trial by the end of 2018. We are also concurrently conducting a long term safety trial for arbaclofen ER.
We seek to selectively acquire or in-license approved products and late-stage product candidates that complement our existing product portfolio, pipeline, technology or commercial infrastructure.
If you have an opportunity that you believe would be of interest to Osmotica, please contact our Business Development team at BD@osmotica.com.